

# GENOMIC VALLEY BIOTECH LIMITED

[CIN : L01122HR1994PLC033029]

4 KM Stone, Beri Chhara Road, P.O. Tanda Heri, Tehsil  
Bahadurgarh, District Jhajjar, HARYANA, INDIA - 124 507

genomicvalley@gmail.com

www.genomicvalley.com

+91 9811341542



Date: 13<sup>th</sup> June, 2022

To,  
BSE Limited  
Phiroze Jeejeebhoy Towers,  
Dalal Street, Fort  
Mumbai-400001  
Email ID: [corp.relations@bseindia.com](mailto:corp.relations@bseindia.com)

**Ref: Genomic Valley Biotech Limited (539206/ GVBL)**

**Sub: Disclosure of Related Party Transactions under Regulation 23(9) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 for the half year ended 31.03.2022**

Dear Sir/ Madam,

Pursuant to Regulation 23(9) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby submit the disclosure of Related Party Transactions for the half year ended 31.03.2022.

Please take the above on records.

Thanking you.

Yours sincerely

For Genomic Valley Biotech Limited



Yogesh Agrawal  
Managing Director

DIN: 01165288

Add: G-74, Pushkar Enclave,  
Paschim Vihar Delhi – 110063

Related Party Transactions for Half year ended March 31, 2022

Rs. In Lakhs

S. No	Details of the party (listed entity/subsidiary) entering into the transaction		Details of the counterparty				Value of the related party transaction as approved by the audit committee (see Note 6a)	Value of transaction during the reporting period (see Note 6b)	In case monies are due to either party as a result of the transaction (see Note 1)		In case any financial indebtedness is incurred to make or give loans, inter-corporate deposits, advances or investments				Details of the loans, inter-corporate deposits, advances or investments			
	Name	PAN	Name	PAN	Relationship of the counterparty with the listed entity or its subsidiary	Type of related party transaction (see Note 5)			Opening balance	Closing balance	Nature of indebtedness (loan/ issuance of debt/ any other etc.)	Cost (see Note 7)	Tenure	Nature (loan/ advance/ inter-corporate deposit/ investment)	Interest Rate (%)	Tenure	Secured/ unsecured	Purpose for which the funds will be utilised by the ultimate recipient of funds (end-usage)
1	GENOMIC VALLEY BIOTECH LIMITED	AABC06306R	Mr. Yogesh Agrawal	AAEPA9020A	Managing Director	Remuneration	As per Agreement	5.5	0	0	-	-	-	-	-	-	-	
2						Repayment of Unsecured Loans	As per Agreement	3.27	21.99	18.72	-	-	-	-	-	-	-	-
3			Mr. Navon Kishore Gupta	ACSPG1395A	Relatives of KMP	Remuneration	As per Agreement	1.65	0	0.70	-	-	-	-	-	-	-	
4			Mr. Hamam Prasad	CENPF7637H	Key Managerial Personnel (KMP)	Remuneration	As per Appointment Letter	0.76	0	0.20	-	-	-	-	-	-	-	
5			Mr. Lala Shah	BCHPS516B	Key Managerial Personnel (KMP)	-	-	-	-	-	-	-	-	-	-	-	-	
6			Mrs. Parul Agrawal	AAJPA6441M	Director	-	-	-	-	-	-	-	-	-	-	-	-	
7			Mr. Pradeep Gupta	AANPG0860N	Independent Director	-	-	-	-	-	-	-	-	-	-	-	-	
8			Mr. Satendra Kumar Gosai	AAAPG0884G	Independent Director	-	-	-	-	-	-	-	-	-	-	-	-	

Notes:

- The details in this format are required to be provided for all transactions undertaken during the reporting period. However, opening and closing balances, including commitments, to be disclosed for existing related party transactions even if there is no new related party transaction during the reporting period.
- For companies with financial year ending March 31, this information has to be provided for six months ended September 30 and six months ended March 31. Companies with financial years ending in other months, the six months period shall apply accordingly.
- Each type of related party transaction (for e.g. sale of goods/services, purchase of goods/services or whether it involves a loan, inter-corporate deposit, advance or investment) with a single party shall be disclosed separately and there should be no clubbing or netting of transactions of same type. However, purchase transactions, Summary loans advanced to and received from the same counterparty should be disclosed separately, without any netting off.
- In case of a multi-year related party transaction.
- The aggregate value of such related party transaction as approved by the audit committee shall be disclosed in the column "Value of the related party transaction as approved by the audit committee".
- The value of the related party transaction undertaken in the reporting period shall be reported in the column "Value of related party transaction during the reporting period".
- "Cost" refers to the cost of borrowed funds for the listed entity.
- PANs will not be displayed on the website of the Stock Exchanges.